New pill hopes to tame tough lung cancer
NCT ID NCT07361237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new tablet (HJ-004-02) in 36 adults with advanced non-squamous non-small cell lung cancer that has EGFR mutations. Participants must have tried other treatments without success or be unable to take them. The study checks safety, side effects, and how the drug moves through the body, while also looking for signs of tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200123, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail